Derivative Instruments - Additional Information (Detail) - USD ($) |
3 Months Ended | 9 Months Ended | ||||
|---|---|---|---|---|---|---|
Jun. 30, 2014 |
Sep. 30, 2015 |
Sep. 30, 2014 |
Sep. 30, 2015 |
Sep. 30, 2014 |
Dec. 31, 2013 |
|
| Derivative Instruments And Hedging Activities Disclosures [Line Items] | ||||||
| Number of shares of common stock called by warrants | 1,969,250 | 1,969,250 | ||||
| Addition to Additional-Paid in Capital | $ 48,380 | |||||
| Loss on change in fair value of warrant liability | $ 0 | $ 0 | $ 0 | $ 28,448 | ||
| JB Therapeutics, Inc [Member] | ||||||
| Derivative Instruments And Hedging Activities Disclosures [Line Items] | ||||||
| Number of shares of common stock called by warrants | 301,778 | |||||
| X | ||||||||||
- Definition Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of expense (income) related to adjustment to fair value of warrant liability. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|